Advertisement

Picture Berlin Partner Voices Peter Seeberger Chemistry Transformation 650x100px
Organisation › Details

Revolution Medicines Inc. (RVMD)

REVOLUTION Medicines is a clinical-stage leader in the discovery and development of precise small molecule therapeutics designed to translate frontier oncology targets within notorious pathways to outsmart cancer. It possesses industry-leading oncology drug discovery capabilities built upon deep scientific knowledge of the biology of cancer pathways and innovative, proprietary technologies that enable the creation of small molecules that target atypical drug binding sites. The company’s pipeline includes RMC-4630, a clinical-stage drug candidate that selectively inhibits the activity of SHP2. Additionally, the company is developing a broad portfolio of inhibitors of other key frontier oncology targets within the notorious RAS pathway, as well as the related PI3K/AKT/mTOR cascade. These include multiple mutant RAS proteins, with its KRASG12C(GTP) program currently in lead optimization; 4EBP1/mTORC1, with a development candidate, RMC-5552, currently advancing into IND-enabling studies; and SOS1, a discovery-stage program. *

 

Period Start 2018-07-18 existent
Products Industry SHP2 inhibitor
  Industry 2 drug discovery
Person Person Goldsmith, Mark A. (Revolution Medicines 201807 CEO)
     
Region Region Redwood City, CA
  Country United States (USA)
  Street 700 Saginaw Drive
  City 94063 Redwood City, CA
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for »About Section«: Revolution Medicines, Inc.. (7/9/19). "Press Release: Revolution Medicines Closes $100 Million Financing to Advance Pipeline of Novel Therapies Addressing Frontier Targets in RAS-Dependent Cancers". Redwood City, CA.
     
   
Record changed: 2023-07-10

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Revolution Medicines Inc. (RVMD)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x300px




» top